Founder, CEO, & Chairman of the Board @SageMedic, Investor, AI & Life Sciences, Mentor & Board Member, Former UCSF Adjunct Professor

California-licensed physician, clinical researcher with 100+ publications including NEJM, impact investor, board member and advisor to over a dozen of life science startups. MD/PhD from the University of Giessen, Germany, and MBA from Wharton, U Penn.

Founder, Aware Coaching: Dedicated to helping couples survive and grow from the trauma of brain cancer

Aware Coaching, founded by Jason and Tracy Binder, is dedicated to helping couples survive and grow from the trauma of brain cancer.

In February 2022, Tracy was diagnosed with glioblastoma with a primitive neuronal component (GBM-PNC), a rare and aggressive brain cancer. Despite the daunting prognosis, Tracy and Jason faced this challenge with unwavering faith, resilience, and community support. Their journey through multiple surgeries, radiation therapy, chemotherapy and the emotional toll of the diagnosis has profoundly shaped their approach to marriage and parenting. They understand the immense strain a brain cancer diagnosis can place on relationships and are committed to providing the support and tools necessary to navigate these challenges.

Founder & CEO at REPROSENT transforming cancer care with patient symptom data and AI | YC S21

REPROSENT captures longitudinal patient symptom data, and leverages it with AI for continuous process improvement in treating cancer. Using patient symptom data as a novel biomarker creates a new category of diagnostic tools, enabling early detection of treatment efficacy and progression of disease, predicting adverse events, and creating a feedback loop based on real patient experience.

2 exits, 1 patent, a career of problem solving. LightLogic (Intel), OnCue (Verizon), True Key, Ciitizen (Invitae). Lost my dad due to an adverse immunotherapy reaction leading me to found REPROSENT.  

Co-Founder Wild Type Advocates | DORIS.Health™ an AI oncology platform

President and Co-Founder of Wild Type Advocates, an AI-driven oncology startup revolutionizing cancer care through custom large language models (LLMs). With over 25 years of experience in biotech commercialization, research, business development, and analytics, 

Dave has been key to launching high-profile drugs like Celebrex, Humira, Trintellix, Epidiolex, and Tepezza. His AI expertise spans from early Expert Systems (1990s) to Neural Network models (2000s) and Machine Learning for rare patient finding (2010s).

Dave's focus today is on Wild Type's oncology-specific language model, DORIS™, a Cancer GPT, which aims to streamline workflows and improve patient outcomes.

A Kellogg MBA and Purdue engineer, Dave now specializes in oncology and orphan drug product launches. Passionate about transforming cancer care, Dave is committed to empowering BOTH healthcare professionals and patients.

Personally touched by cancer, Dave recently lost his business partner and his best friend began chemotherapy in September. He is also a proud father of five.

https://www.linkedin.com/in/djhia/

CEO & Co-founder, We Are Here (Techstars Heath '24) | Cancer Advocate

Carolyn Treviño Jenkins is a serial tech entrepreneur with multiple exits up to 10x return on capital. As a technology executive she led companies to win international awards for outstanding customer success, as well as national awards for growth and cutting-edge work in people management. With over 25 years of experience, Carolyn has led companies through economic downturns, as well as through rapid growth (organic and through M&A). 

Carolyn believes a culture of strategy execution and accountability can be achieved with servant and compassionate leadership. High performance has enabled Carolyn to break down gender and ethnic barriers. She is a mentor to many business leaders and is a frequent public speaker. She holds a Master of Business Administration from the University of Texas at Austin’s Red McCombs School of Business, and lives in Austin with her husband and two dogs.  She is the proud mother of three adult children. Her passions are advocating for those with special needs, supporting the U.S. Coast Guard, and making meaningful connections for others.

Carolyn is also a survivor, which fuels her passion for her latest endeavor.

Founder Research to the People @ Stanford Medicine

Founder & CEO Rabble Health | Advocacy Board Chair, Children's Hospital Los Angeles

Founder/CEO of Rabble Health Inc, a digital health company focused on helping people facing complex disease gain access to innovation in medicine.  Aubrey is a former biopharma executive turned health tech entrepreneur following her son’s successful journey with Acute Myeloid Leukemia.  She is passionate about helping more patients self-advocate, improving shared decision making, and evolving clinical decision support.  She received her MS Biology from University of Colorado, and MBA from UCLA Anderson School of Management.  

Founder/CEO @Translating Science PBC

Frank Austin Nothaft is an engineer-scientist focused on making genomic data accessible through open source software. Frank is currently working on Translating Science PBC, building tools to help patients understand their genomic test results.

Previously, Frank led the development of the Lens platform at Tempus Labs, and the Healthcare and Life Sciences team at Databricks. At Databricks, Frank led multiple product launches, including Glow and the Databricks Unified Analytics Platform for Genomics.

Physician-Scientist Fellow @ MIT
CEO & Co-Founder @ Nine Diagnostics

Physician-scientist-entrepreneur developing and translating biomedical optical technologies and nanotechnologies from the bench to the bedside in oncology, cardiovascular, and hematology. Passionate about moving new technologies from ideation to impact, training the future generations of physician-scientists, physicians, scientists, engineers, and entrepreneurs, and building communities and collaborations in healthcare innovation, research, and medicine.

Co-founder of Nine Diagnostics, American Physician Scientists Association, Rice Alumni in Medicine, MIT COVID-19 Challenge, and MIT Hacking Racism Challenge, and former co-director for MIT Hacking Medicine.

CEO and Founder, Genomic Expression

Gitte Pedersen, CEO is a former executive at Novo Nordisk. She has advised the Danish Government and early-stage biotech companies regarding their corporate development in the US. Started Genomic Expression with her brother when their parents got diagnosed with cancer, realizing that standard of care would not be effective  Launching the RNA Platform OneRNA® as a treatment navigation diagnostic tool in breast and ovarian cancer. OneRNA can assist the 50-80% of patients that do not respond to standard of care to find a clinical study or an FDA-approved drug that is specifically interrogating the individual patients tumor. OneRNA® is clinically validated with high diagnostic yield (99%) primarily for grants $6.5M. We generated lifetime revenue of $4.5M and closed convertible notes of $1.7M - most have converted. Raising a bridge of $1.2M and a series A of $6M+  check us out here https://www.genomicexpression.com/invest and link up with me here https://www.linkedin.com/in/proximity/

CEO at Sagely Health/ CMO at Accent Tx

As a career physician-scientist with 12 years of clinical experience as a pediatric oncologist (Johns Hopkins, NCI, and Dana Farber) and 20 years of translational early clinical oncology drug development experience 

(Genentech, Novartis, Sanofi, multiple biotechs), I established Sagely Health, a health IT company, in 2014 to tackle the biggest problem facing cancer patients today: a lack of information and support that can produce their best possible outcome. On the way to constructing a web-based platform that aims to one day serve millions of patients, we have helped more than a hundred adults and children through a personalized service where we use our system to provide tremendous value by identifying scientifically justified innovative therapies (e.g. clinical trials) and personalized care (e.g. diagnostics) that otherwise remain unknown. My clinical experience, scientific background with Bert Vogelstein, as well as my pharma experience provide the insights I needed to build the system that helps patients on a step by step basis. 

Co-Founder & CEO @DatAnon | Pioneering Patient Response in Cancer Treatment and Clinical Trials | Assoc. Professor @Karolinska Institute

Associate Professor of Bioinformatics at the Karolinska Institute and Co-founder at DatAnon Corporation, which has the goal of using novel topological data analysis tools for precision oncology. DatAnon’s proprietary gene expression signatures and methods can detect subgroups of patient responders, which help match patients to the best treatments as well as increase chances of patients responding in clinical trials.

President and CEO at Protean BioDiagnostics Inc

Dr. Magliocco is a board-certified Pathologist and Professor of Oncology and Pathology with over 30 of years of experience in tissue pathology, medical research, molecular diagnostics, liquid biopsy, genetics, digital image analysis and clinical trials. He has founded and led multiple clinical laboratories and has overseen the deployment of numerous new laboratory tests in his career in both Canada and the USA. He has published over 200 research articles, has numerous patents issued and applied, and is a frequent invited speaker to international diagnostic technology meetings.

He was Chair of Pathology at the Moffitt Cancer Center, Scientific Director of the tissue core at Moffitt, and Chair of Pathology in the national cooperative groups RTOG and NRG oncology. He has developed new digital image analysis methods and has created numerous new diagnostic tests used to aid selection of treatment plans for patients with breast, ovary, lung, bladder and other cancers. He founded fellowship programs in digital imaging and molecular diagnostics at the Moffitt Cancer Center. He founded the hereditary cancer program in Saskatchewan and was the pathology leader of numerous tumor groups at the Tom Baker Cancer Center in Canada.

He also served as medical and scientific director of multiple regional and national tumor banks. His deep knowledge of molecular biology and medicine enable him to identify tests and tools that are unique in their ability to contribute to the future of medical diagnostics. His interest and aptitude for business enables him to create a viable pathway for implementation of these tests and tools. His vision is to move medical diagnostics forward to keep pace with scientific discoveries.

Most recently he has founded Protean BioDiagnostics. He has developed the unique Oncology MAPS system, which is currently the only comprehensive precision medicine system aimed at supporting community-based cancer patients and their doctors.